Guardant Health Must Pay $83.4 Million in a DNA Sequencing Patent Case

Precision oncology company Guardant Health GH.O was hit with an $83.4 million verdict by a jury in Delaware federal court, which found that its cancer-testing kits violate the patent rights of biotech company TwinStrand Biosciences and the University of Washington.

The jury said on Tuesday that Guardant’s genetic-sequencing technology infringes two patents and that the infringement was willful, which could lead to the award being multiplied.

Guardant co-founder and co-CEO Helmy Eltoukhy said in a statement on Wednesday that the company strongly disagrees with the decision and will “vigorously appeal.” Eltoukhy also said that the decision “ignores the strengths and merits of our R&D and intellectual property, which we painstakingly developed for over a decade.”

Read the source article at Nasdaq